IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v18y2017i7d10.1007_s10198-016-0836-8.html
   My bibliography  Save this article

Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany

Author

Listed:
  • Peter Greven

    (Institute of Child and Adolescent Psychiatry, Psychotherapy and Social Pediatrics
    H:G University of Health and Sport, Technology and Arts)

  • Vanja Sikirica

    (Shire)

  • Yaozhu J. Chen

    (IMS Health, Inc)

  • Tammy G. Curtice

    (Shire)

  • Charles Makin

    (IMS Health, Inc)

Abstract

Background Attention-deficit/hyperactivity disorder (ADHD) imposes a substantial burden on patients and their families. Objective A retrospective, propensity score-matched cohort study compared treatment patterns, healthcare resource utilization (HRU) and costs among children/adolescents with ADHD aged 6–17 years at treatment initiation (index) in Germany who received atomoxetine (ATX) or long-acting methylphenidate (LA-MPH) monotherapy. Methods Patients received at least one prescription for their index medication (ATX/LA-MPH) during 2006–2010; the first prescription marked the index date. ATX- and LA-MPH-indexed cohorts were matched 1:1 (n = 737); a patient subset was identified that had not received ADHD-indicated medications in 12 months prior to index (novel initiators: ATX, n = 486; LA-MPH, n = 488). Treatment patterns were evaluated among novel initiators, and HRU and costs among the matched cohorts in the 12 months after index. Results No significant differences in baseline characteristics were found between the novel initiator patient subsets. ATX-indexed novel initiators had significantly longer persistence to index medication [mean (standard deviation; SD) days: 222.0 (133.9) vs 203.2 (135.0), P = 0.029) but higher switching rates (8.8 vs 5.5 %, P = 0.045) than LA-MPH-indexed novel initiators. The total ATX-indexed cohort required more prescriptions [any medication; mean (SD): 20.9 (11.5) vs 15.7 (9.0), P

Suggested Citation

  • Peter Greven & Vanja Sikirica & Yaozhu J. Chen & Tammy G. Curtice & Charles Makin, 2017. "Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 893-904, September.
    • Handle: RePEc:spr:eujhec:v:18:y:2017:i:7:d:10.1007_s10198-016-0836-8
    DOI: 10.1007/s10198-016-0836-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-016-0836-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-016-0836-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Sebastian Braun & Jan Zeidler & Roland Linder & Susanne Engel & Frank Verheyen & Wolfgang Greiner, 2013. "Treatment costs of attention deficit hyperactivity disorder in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 939-945, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Camilla Nystrand & Inna Feldman & Pia Enebrink & Filipa Sampaio, 2019. "Cost-effectiveness analysis of parenting interventions for the prevention of behaviour problems in children," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-17, December.

    More about this item

    Keywords

    Atomoxetine; Methylphenidate; Attention-deficit/hyperactivity disorder; Cost of illness;
    All these keywords.

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:18:y:2017:i:7:d:10.1007_s10198-016-0836-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.